Cite

    Gu, K. et al. (2022). A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects. Clinical and translational science. 15 (7), pp. 1592-1598. [Online].